NCOA4 (NM_001145260) Human Tagged ORF Clone Lentiviral Particle
CAT#: RC226666L4V
- LentiORF®
-
Lenti ORF particles, NCOA4 (mGFP-tagged)-Human nuclear receptor coactivator 4 (NCOA4), transcript variant 1, 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 12,540.00
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | NCOA4 (NM_001145260) Human Tagged ORF Clone Lentiviral Particle |
Synonyms | ARA70; ELE1; PTC3; RFG |
Vector | pLenti-C-mGFP-P2A-Puro |
ACCN | NM_001145260 |
ORF Size | 1950 bp |
Sequence Data |
The ORF insert of this clone is exactly the same as(RC226666).
|
OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
Reference Data | |
RefSeq | NM_001145260.1, NP_001138732.1 |
RefSeq ORF | 1953 bp |
Locus ID | 8031 |
Protein Families | Druggable Genome, Transcription Factors |
Protein Pathways | Pathways in cancer, Thyroid cancer |
MW | 73.5 kDa |
Gene Summary | This gene encodes an androgen receptor coactivator. The encoded protein interacts with the androgen receptor in a ligand-dependent manner to enhance its transcriptional activity. Chromosomal translocations between this gene and the ret tyrosine kinase gene, also located on chromosome 10, have been associated with papillary thyroid carcinoma. Alternatively spliced transcript variants have been described. Pseudogenes are present on chromosomes 4, 5, 10, and 14. [provided by RefSeq, Feb 2009] |
Documents
Product Manuals |
FAQs |
SDS |